Characteristics of 195 multiple myeloma patients
| . | ATE, n = 11 . | No ATE, n = 184 . |
|---|---|---|
| Male sex, no. (%) | 9 (82) | 104 (57) |
| Median age at enrollment, y (range) | 58 (42-62) | 56 (29-65) |
| B2 microglobulin, mg/L | 2.4 (0.8-44.0) | 3.4 (1.4-11.8) |
| Monoclonal protein, IgD, IgA, and IgG, no. (%) | ||
| Kappa | 10 (91) | 127 (69) |
| Lambda | 1 (9) | 51 (28) |
| Unknown | 0 | 6 (3) |
| ISS stage, no. (%) | ||
| I | 5 (63) | 63 (46) |
| II | 2 (25) | 39 (29) |
| III | 1 (13) | 34 (25) |
| Treatment, no. (%) | ||
| VAD | 6 (55) | 97 (53) |
| TAD | 2 (27) | 42 (23) |
| PAD | 3 (27) | 45 (24) |
| Durie-Salmon, no. (%) | ||
| II | 2 (18) | 33 (18) |
| III | 9 (82) | 148 (81) |
| Long-term VKA or therapeutic LMWH,* no. (%) | 4 (36) | 24 (13) |
| Long-term aspirin,* no. (%) | 1 (9) | 7 (4) |
| Fibrinogen, g/L (range) | 3.50 (2.2-6.2) | 3.50 (1.60-7.70) |
| Factor VIII:C, IU/mL (range) | 2.93 (1.16-6.45) | 2.15 (0.74-6.48) |
| VWF Ag, U/mL (range) | 2.54 (0.88-7.26) | 2.09 (0.44-8.12) |
| Protein C activity, IU/mL (range) | 1.00 (0.79-1.54) | 0.97 (0.45-2.03) |
| Protein S activity, IU/mL (range) | 0.86 (0.44-1.37) | 0.76 (0.26-1.81) |
| Antithrombin, IU/mL (range) | 1.05 (0.73-1.50) | 0.99 (0.51-1.52) |
| PT 20210G>A, no. (%) | 0 (0) | 7 (5) |
| Factor V Leiden, no. (%) | 0 (0) | 5 (3) |
| Diabetes, no. (%) | 2 (18) | 12 (7) |
| Hypertension, no. (%) | 6 (55) | 40 (22) |
| Hyperlipidemia, no. (%) | 1 (9) | 12 (7) |
| Smoking history, no. (%) | 7 (64) | 42 (23) |
| . | ATE, n = 11 . | No ATE, n = 184 . |
|---|---|---|
| Male sex, no. (%) | 9 (82) | 104 (57) |
| Median age at enrollment, y (range) | 58 (42-62) | 56 (29-65) |
| B2 microglobulin, mg/L | 2.4 (0.8-44.0) | 3.4 (1.4-11.8) |
| Monoclonal protein, IgD, IgA, and IgG, no. (%) | ||
| Kappa | 10 (91) | 127 (69) |
| Lambda | 1 (9) | 51 (28) |
| Unknown | 0 | 6 (3) |
| ISS stage, no. (%) | ||
| I | 5 (63) | 63 (46) |
| II | 2 (25) | 39 (29) |
| III | 1 (13) | 34 (25) |
| Treatment, no. (%) | ||
| VAD | 6 (55) | 97 (53) |
| TAD | 2 (27) | 42 (23) |
| PAD | 3 (27) | 45 (24) |
| Durie-Salmon, no. (%) | ||
| II | 2 (18) | 33 (18) |
| III | 9 (82) | 148 (81) |
| Long-term VKA or therapeutic LMWH,* no. (%) | 4 (36) | 24 (13) |
| Long-term aspirin,* no. (%) | 1 (9) | 7 (4) |
| Fibrinogen, g/L (range) | 3.50 (2.2-6.2) | 3.50 (1.60-7.70) |
| Factor VIII:C, IU/mL (range) | 2.93 (1.16-6.45) | 2.15 (0.74-6.48) |
| VWF Ag, U/mL (range) | 2.54 (0.88-7.26) | 2.09 (0.44-8.12) |
| Protein C activity, IU/mL (range) | 1.00 (0.79-1.54) | 0.97 (0.45-2.03) |
| Protein S activity, IU/mL (range) | 0.86 (0.44-1.37) | 0.76 (0.26-1.81) |
| Antithrombin, IU/mL (range) | 1.05 (0.73-1.50) | 0.99 (0.51-1.52) |
| PT 20210G>A, no. (%) | 0 (0) | 7 (5) |
| Factor V Leiden, no. (%) | 0 (0) | 5 (3) |
| Diabetes, no. (%) | 2 (18) | 12 (7) |
| Hypertension, no. (%) | 6 (55) | 40 (22) |
| Hyperlipidemia, no. (%) | 1 (9) | 12 (7) |
| Smoking history, no. (%) | 7 (64) | 42 (23) |
ATE indicates arterial thrombosis; ISS, International Scoring System; IgD, immunoglobulin D; VAD, vincristine, doxorubicin, and dexamethasone; TAD, thalidomide, doxorubicin, and dexamethasone; PAD, bortezomib, doxorubicin, and dexamethasone; VKA, vitamin K antagonist; LMWH, low molecular weight heparin; VWF, von Willebrand Factor; and PT, prothrombin.
Long-term indicates at least 6 months of treatment.